Topical steroid treatment of allergic rhinitis decreases nasal fluid TH2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-γ, IL-1β, TNF-α, or neutrophils

Abstract

Background: Topical treatment with glucocorticoids (GCs) is known to decrease eosinophils but not neutrophils in patients with allergic rhinitis. Objective: We sought to examine whether the differential effects of GC treatment on eosinophils and neutrophils are mirrored by differential effects on TH1/TH2 cytokines and the neutrophil-associated cytokines IL-1β and TNF-α. Methods: Differential counts of eosinophils and neutrophils in nasal fluids from 60 children with seasonal allergic rhinitis treated with a topical GC were examined after staining with May-Grünwald-Giemsa stain. Nasal fluid levels of IFN-γ, IL-4, IL-6, IL-10, IL-1β, and TNF-α were examined with ELISA, and IgE and eosinophil cationic protein (ECP) levels were examined with RIA. Results: After GC treatment, there was a statistically significant decrease of the TH2 cytokines IL-4, IL-6, and IL-10, as well as ECP and IgE. By contrast, there were no significant changes of the levels of IFN-γ, IL-1β, TNF-α, or neutrophils. In the GC-treated patients IL-1β and TNF-α levels correlated with neutrophils and ECP, and IL-1β correlated with eosinophils. Furthermore, ECP correlated with both eosinophils and neutrophils. Neither IL-1β nor TNF-α correlated with IgE. Patients with high neutrophil counts after GC treatment were found to have significantly higher eosinophil counts and ECP than patients with low counts. Conclusions: The beneficial effects of topical treatment with GC in patients with allergic rhinitis could be attributed to downregulation of TH2 cytokines, with an ensuing decrease of eosinophils, ECP, and IgE. It is possible that neutrophils could counteract the beneficial effects of GCs by releasing the proinflammatory cytokines IL-1β and TNF-α. (J Allergy Clin Immunol 2000;106:307-12.)